Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dr Ashleys
Riga, Latvia
- Ownership
- Private
- Development stage
- Other
01
Overview
Dr Ashleys commercially manufactures and distributes over 85 products—including APIs for cancer, infectious disease, and orphan/rare indications—supplying over 300 million annual doses globally, with a focus on underserved health regions and both generic and patented medicines[1][2][4].
- Therapeutic areas
- Infectious DiseasesRare DiseasesGastroenterologyCardiovascularOncologyNeurology
- Modalities
- Small moleculeBiologicRecombinant proteinActive pharmaceutical ingredient
- Industry
- Biotech
02
Partnerships
Impact BioMedical (strategic merger)[2][3][6][7]
Beyond the preview
Go deeper on Dr Ashleys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dr Ashleys.